Modality
Small Molecule
MOA
PLK4i
Target
CD19
Pathway
Sphingolipid
HNSCCLGSHS
Development Pipeline
Preclinical
~Jul 2019
→ ~Oct 2020
Phase 1
Jan 2021
→ Feb 2030
Phase 1Current
NCT08354530
2,178 pts·HS
2021-01→2030-02·Recruiting
2,178 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2030-02-023.8y awayInterim· HS
Trial Timeline
2021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2
P1
Recruit…
Catalysts
Interim
2030-02-02 · 3.8y away
HS
Recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT08354530 | Phase 1 | HS | Recruiting | 2178 | HAM-D |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-8662 | Pfizer | NDA/BLA | CD19 | |
| NVS-6974 | Novartis | Preclinical | CD19 | |
| Voxarasimod | Merck & Co | Phase 1/2 | CD19 | |
| AMG-2597 | Amgen | Phase 2/3 | CD38 | |
| Riluinavolisib | Moderna | NDA/BLA | KIF18A | |
| Tirarelsin | TG Therapeutics | NDA/BLA | CD19 | |
| Liravorutinib | Biomea Fusion | Phase 1/2 | GPRC5D | |
| VYG-2926 | Voyager | NDA/BLA | CD19 | |
| SDG-1247 | Schrodinger | Phase 1 | CD19 | |
| Talatuximab | Sobi | Phase 1/2 | CD19 |